Agenda for October 2026 Gastrointestinal Advisory Committee meeting
Information on what the Gastrointestinal Advisory Committee will be considering at its upcoming meeting in October 2026.
Matters Arising
Vedolizumab Subcutaneous (Branded as ENTYVIO) for Ulcerative colitis and Crohn’s Disease
The Committee will discuss vedolizumab as a subcutaneous injection option for people living with ulcerative colitis or Crohn’s disease, to maintain disease control after initial intravenous treatment.
Application for vedolizumab sc(external link)
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.